Q1 Earnings Estimate for TNXP Issued By Zacks Small Cap

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Stock analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for shares of Tonix Pharmaceuticals in a report issued on Thursday, April 3rd. Zacks Small Cap analyst D. Bautz forecasts that the company will post earnings per share of ($3.37) for the quarter. The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($1,762.50) per share. Zacks Small Cap also issued estimates for Tonix Pharmaceuticals’ Q2 2025 earnings at ($12.49) EPS, Q3 2025 earnings at ($4.49) EPS, Q4 2025 earnings at ($5.03) EPS, FY2025 earnings at ($16.43) EPS and FY2026 earnings at ($7.80) EPS.

TNXP has been the topic of several other reports. StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a “sell” rating on the stock. Noble Financial reiterated an “outperform” rating and issued a $70.00 price objective on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.

Tonix Pharmaceuticals Trading Up 13.8 %

Shares of NASDAQ TNXP opened at $17.80 on Monday. The company has a market cap of $114.54 million, a PE ratio of 0.00 and a beta of 1.50. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The firm’s 50 day moving average price is $17.03 and its 200-day moving average price is $20.29. Tonix Pharmaceuticals has a 52-week low of $6.76 and a 52-week high of $672.00.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.20 million.

Institutional Trading of Tonix Pharmaceuticals

Large investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in Tonix Pharmaceuticals by 1,600.1% in the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock worth $650,000 after purchasing an additional 1,855,907 shares during the last quarter. Jane Street Group LLC increased its holdings in Tonix Pharmaceuticals by 5,932.3% during the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after buying an additional 1,635,119 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Tonix Pharmaceuticals in the fourth quarter worth approximately $526,000. Northern Trust Corp purchased a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth $162,000. Finally, PFG Investments LLC purchased a new stake in shares of Tonix Pharmaceuticals in the 4th quarter worth $72,000. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.